2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
olokizumab (CDP6038)<br />
A highly potent anti-IL6 inhibitor with a novel mechanism of action<br />
First in a new class of anti-IL-6 inhibitors that selectively blocks<br />
the final assembly step of the IL-6 signaling complex<br />
Phase 1b: Study in RA patients completed in Q4 <strong>2010</strong><br />
• Potently induced and sustained CRP suppression<br />
• Well tolerated at all doses<br />
• Half-life of 31 days and absolute bioavailability of 75% (SC)<br />
• Low incidence of immunogenicity<br />
Phase 2b: SC Dose ranging study initiated ahead of plan in Q4 <strong>2010</strong><br />
• >200 patients with active RA who have failed TNF blocker therapy<br />
• Active comparator Actemra ® IV<br />
• Headline <strong>results</strong> Q3 2012 expected<br />
52
Change language